| Literature DB >> 31554641 |
Lin Wang1, Husam Babikir1, Sören Müller1, Garima Yagnik1, Karin Shamardani1, Francisca Catalan1, Gary Kohanbash2, Beatriz Alvarado1,3, Elizabeth Di Lullo3, Arnold Kriegstein3, Sumedh Shah1, Harsh Wadhwa1, Susan M Chang1, Joanna J Phillips1, Manish K Aghi1, Aaron A Diaz4.
Abstract
Although tumor-propagating cells can be derived from glioblastomas (GBM) of the proneural and mesenchymal subtypes, a glioma stem-like cell (GSC) of the classic subtype has not been identified. It is unclear whether mesenchymal GSCs (mGSC) and/or proneural GSCs (pGSC) alone are sufficient to generate the heterogeneity observed in GBM. We performed single-cell/single-nucleus RNA sequencing of 28 gliomas, and single-cell ATAC sequencing for 8 cases. We found that GBM GSCs reside on a single axis of variation, ranging from proneural to mesenchymal. In silico lineage tracing using both transcriptomics and genetics supports mGSCs as the progenitors of pGSCs. Dual inhibition of pGSC-enriched and mGSC-enriched growth and survival pathways provides a more complete treatment than combinations targeting one GSC phenotype alone. This study sheds light on a long-standing debate regarding lineage relationships among GSCs and presents a paradigm by which personalized combination therapies can be derived from single-cell RNA signatures, to overcome intratumor heterogeneity. SIGNIFICANCE: Tumor-propagating cells can be derived from mesenchymal and proneural glioblastomas. However, a stem cell of the classic subtype has yet to be demonstrated. We show that classic-subtype gliomas are comprised of proneural and mesenchymal cells. This study sheds light on a long-standing debate regarding lineage relationships between glioma cell types.See related commentary by Fine, p. 1650.This article is highlighted in the In This Issue feature, p. 1631. ©2019 American Association for Cancer Research.Entities:
Mesh:
Year: 2019 PMID: 31554641 PMCID: PMC7161589 DOI: 10.1158/2159-8290.CD-19-0329
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272